Radiation Treatment Of Prostate Cancer

Radiation Treatment Of Prostate Cancer.
Smoking doubles the chances that a prostate cancer lenient will comprehend his disease spread and that he will eventually die from his illness, a new look finds. "Basically we found that people who smoke had a higher risk of their tumor coming back, of it spreading and, ultimately, even expiring of prostate cancer," said study co-author Dr Michael Zelefsky. He is villainy chair of clinical research in the department of radiation oncology at Memorial Sloan Kettering Cancer Center in New York City north carolina. "But interestingly, this applied only to 'current smokers' who were smoking around the duration they received surface beam therapy," Zelefsky added, referring to the flag form of radiation treatment for prostate cancer.

So "Former smokers did not have the increased hazard for disease spread and recurrence that current smokers did. "However, we also looked at how smoking influenced treatment side effects," from the radiation treatment, which can include rectal bleeding and/or constant and urgent urination hgh drops. "And we saw that both patients who smoked and former smokers seemed to have a higher jeopardize of urinary-related side effects after therapy".

Zelefsky and his colleagues reported the findings online Jan 27, 2015 in the paper BJU International. The research team aciculiform out that 19 percent of American adults smoke. To explore the impact of smoking yesterday on prostate cancer treatment and progression, the study authors focused on nearly 2400 patients who underwent care for prostate cancer between 1988 and 2005. Nearly 50 percent were identified as "former smokers," even if they had only kicked their practice shortly before beginning cancer treatment.

Disease progression, relapse, symptoms and deaths were all tracked for an general of eight years, as were all reactions to the radiation treatment. The researchers predetermined that the likelihood of surviving prostate cancer for a decade without experiencing any disease recurrence was about 66 percent to each patients who had never smoked. By comparison, that figure fell to 52 percent middle patients who were current smokers.

New Blood Test Can Detect Prostate Cancer More Accurately And Earlier

New Blood Test Can Detect Prostate Cancer More Accurately And Earlier.
A rejuvenated blood evaluation to spot a cluster of specific proteins may call the presence of prostate cancer more accurately and earlier than is now possible, new research suggests. The test, which has thus far only been assessed in a aviator study, is 90 percent accurate and returned fewer false-positive results than the prostate individual antigen (PSA) test, which is the current clinical standard, the researchers added more information. Representatives of the British followers that developed the test, Oxford Gene Technology in Oxford, presented the findings Tuesday at the International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Denver, hosted by the American Association for Cancer Research.

The assess looks for auto-antibodies for cancer, comparable to the auto-antibodies associated with autoimmune diseases such as order 1 diabetes, rheumatoid arthritis and lupus. "These are antibodies against our own proteins," explained John Anson, Oxford's sinfulness president of biomarker discovery. "We're stressful to look for antibodies generated in the premature stages of cancer home page. This is an exquisitely sensitive mechanism that we're exploring with this technology".

Such a exam generates some excitement not only because it could theoretically detect tumors earlier, when they are more treatable, but auto-antibodies can be "easily detected in blood serum. It's not an invasive technique. It's a imbecile blood test". The researchers came up with groups of up to 15 biomarkers that were aid in prostate cancer samples and not present in men without prostate cancer. The investigation also was able to differentiate actual prostate cancer from a more benign condition.

Because a flagrant is currently pending, Anson would not list the proteins included in the test. "We are wealthy on to a much more exhaustive follow-on study. At the moment, we are taking over 1,800 samples, which includes 1,200 controls with a intact range of 'interfering diseases' that men of 50-plus are prone to and are running a very large analytical validation study".

Statins May Reduce The Risk Of Prostate Cancer

Statins May Reduce The Risk Of Prostate Cancer.
Cholesterol-lowering statins significantly trim prostate tumor inflammation, which may domestic lower the risk of disease progression, young study findings suggest female. Duke University Medical Center researchers found that the use of statins before prostate cancer surgery was associated with a 69 percent reduced distinct possibility of inflammation basically prostate tumors.

For the study, the researchers examined tissue samples of prostate tumors from 236 men undergoing prostate cancer surgery drops. The patients included 37 who took statins during the year ex to their surgery.

Overall, 82 percent of the men had traitorous cells in their prostate tumors and about one-third had decided tumor inflammation. After they accounted for factors such as age, tribe and body-mass index (a measurement that is based on weight and height), the Duke team concluded that statin use was associated with reduced sore within tumors.

Smoking And Weight Gain Increases The Death Rate From Prostate Cancer

Smoking And Weight Gain Increases The Death Rate From Prostate Cancer.
Men treated for prostate cancer who smoke or put on surplus pounds jack up their distinction of disease recurrence and of dying from the illness, two new studies show paxil cr for panic attacks. The findings were presented Tuesday at the American Association for Cancer Research's annual joining in Washington, DC.

In the head report, a team led by Dr Jing Ma, an associate professor of pharmaceutical at Brigham and Women's Hospital in Boston, found that obesity and smoking may not be risk factors for developing prostate cancer, but they do grow the odds that a man who has the illness will die from it vitohealth.men. Being obese and smoking "predispose men to a significantly high risk of cancer-specific and all-cause mortality," Ma said during a Tuesday matinal news conference.

"Compared to lean non-smokers, obese smokers had the highest danger of prostate cancer mortality". For the study, Ma's team collected data on more than 2700 men with prostate cancer who took duty in the Physicians Health Study. Over 27 years of follow-up, 882 of the men died, 11 percent from the cancer.

The researchers found that both tonnage augmentation and smoking boosted the risk for dying from the cancer. In fact, every five-point lengthen in body mass index (BMI) increased the risk for dying from prostate cancer by 52 percent. BMI is a height of height versus weight, with the threshold of overweight set at a BMI of 25 and the door-sill for obesity set at a BMI of 30.

In addition, men who smoked increased their risk for dying from the cancer by 55 percent, compared with men who never smoked, the swat found. "These data underscore the extremity for implementing effective preventive strategies for weight control and reducing tobacco use in both flourishing men as well as prostate cancer patients".

In a second report, a team led by Corinne E Joshu, a postdoctoral person in the department of epidemiology at Johns Hopkins Bloomberg School of Public Health, found that men who gained force after having their prostate removed were almost twice as likely to visit with their cancer return as were men who maintained their weight. "Weight gain may increase the risk of prostate cancer recurrence after prostatectomy," Joshu said during the AACR dirt conference.

"Obesity, especially among unoccupied men, may also contribute to the risk of prostate cancer recurrence". For the study, Joshu's span collected data on more than 1300 men with localized prostate cancer who underwent prostatectomy between 1993 and 2006. In addition, the men completed a size up on diet, lifestyle and other factors such as weight, level and physical activity five years before surgery and again one year after the procedure.

Effect Of Anesthesia In Surgery Of Prostate Cancer

Effect Of Anesthesia In Surgery Of Prostate Cancer.
For men having prostate cancer surgery, the species of anesthesia doctors use might kind a metamorphosis in the odds of the cancer returning, a new study suggests. Researchers found that of nearly 3300 men who underwent prostate cancer surgery, those who were given both mongrel and regional anesthesia had a lower risk of seeing their cancer furtherance than men who received only general anesthesia order vigaplus. Over a period of 15 years, about 5 percent of men given only imprecise anesthesia had their cancer recur in their bones or other sites, the researchers said.

That compared with 3 percent of men who also received regional anesthesia, which typically meant a spinal injection of the anaesthetic morphine, gain a numbing agent. None of that, however, proves that anesthesia choices immediately affect a prostate cancer patient's prognosis testimoni vigrx nebraska. "We can't conclude from this that it's cause-and-effect," said major researcher Dr Juraj Sprung, an anesthesiologist at the Mayo Clinic in Rochester, Minn.

But one theory is that spinal painkillers - with the opioid morphine - can depute a difference because they curb patients' need for opioid drugs after surgery. Those post-surgery opioids, which change the whole body, may decrease the immune system's effectiveness. That's potentially leading because during prostate cancer surgery, some cancer cells usually be forgotten by into the bloodstream - and a fully functioning immune response might be needed to kill them off. "If you dodge opioids after surgery, you may be increasing your ability to fight off these cancer cells.

The study, reported online Dec 17, 2013 in the British Journal of Anaesthesia, is not the in front to see a bond between regional anesthesia and a lower risk of cancer recurrence or progression. Some past studies have seen a nearly the same pattern in patients having surgery for breast, ovarian or colon cancer. But those studies, such as the current one, point only to a correlation, not a cause-and-effect link. Dr David Samadi, supervisor of urology at Lenox Hill Hospital in New York City, agreed.

New Ways Of Treating Prostate Cancer And Ovarian Cancer

New Ways Of Treating Prostate Cancer And Ovarian Cancer.
New analysis supports untested ways to treat ovarian and prostate cancer, while producing a fiasco for those with a certain form of colon cancer. Both the ovarian and prostate cancer trials could substitute clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the disease in its advanced stages and more men getting diffusion therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual intersection in Chicago proextender. A third trial, looking at the effectiveness of cetuximab (Erbitux) in treating unfluctuating colon cancer patients, found the treat made little difference to their survival.

The first study found that adding Avastin to sample chemotherapy (carboplatin and paclitaxel) and continuing with "maintenance" Avastin after chemo in fact slowed the time-to-disease recurrence in women with advanced ovarian cancer. Avastin is an anti-angiogenic drug, drift it interferes with a tumor's blood supply worldplusmed.net. "This is the first molecular-targeted and first anti-angiogenesis cure to demonstrate benefit in this population and, combined with chemotherapy followed by Avastin maintenance, should be considered as one typical option for women with this disease," said lead researcher Dr Robert A Burger, numero uno of the Women's Cancer Center at Fox Chase Cancer Center in Philadelphia.

So "This is a immature potential treatment paradigm for stage 3 and 4 ovarian cancer," added Dr Jennifer Obel, an attending medical doctor at Northshore University Health System and mediator of a Sunday news conference at which these results were presented. The phase 3 enquiry involved almost 1,900 women with stage 3 and stage 4 ovarian cancer. Those who received norm chemotherapy plus Avastin, and then maintenance Avastin, for up to 10 months lived just over 14 months without their blight progressing compared with about 10 months for those receiving standard chemotherapy alone.

Those who received chemo bonus Avastin but no maintenance drug lived without a recurrence for 11,3 months, a inconsistency not considered statistically significant. "I'm cautiously optimistic about this data. It manifestly shows that those who had maintenance Avastin had improved profession-free survival," said Dr Robert Morgan, co-director of the gynecologic oncology program at City of Hope Cancer Center in Duarte, Calif. "I imagine we have to intermission for longer term outcomes before we make definite conclusions. It's too originally for overall survival benefit data".

However, he pointed out, a four-month difference for progression-free survival is "substantial". Doctors are already using Avastin off-label everywhere to treat ovarian cancer although it is not yet approved for this use. It has been shown to be more agile in this cancer than in many cancers for which it is approved.

Weather Conditions May Affect Prostate Cancer Patients

Weather Conditions May Affect Prostate Cancer Patients.
A redone about links dry, cold weather to higher rates of prostate cancer. While the findings don't strengthen a direct link, researchers suspect that weather may affect blighting and, in turn, boost prostate cancer rates. "We found that colder weather, and obscene rainfall, were strongly correlated with prostate cancer," researcher Sophie St-Hilaire, of Idaho State University, said in a item release.

So "Although we can't say exactly why this correlation exists, the trends are unchanging with what we would expect given the effects of climate on the deposition, absorption, and degradation of persistent basic pollutants including pesticides". St-Hilaire and colleagues studied prostate cancer rates in counties in the United States and looked for links to county weather patterns.

They found a link, and suggest it may exist because chilly weather slows the degradation of pollutants. Prostate cancer will strike about one in six men, according to curriculum vitae information in the study. Reports suggest it's more common in the northern hemisphere.

Slowly Progressive Prostate Cancer Need To Be Watched Instead Of Treatment

Slowly Progressive Prostate Cancer Need To Be Watched Instead Of Treatment.
For patients with prostate cancer that has a smaller hazard of progression, on the move surveillance, also known as "watchful waiting," may be a suitable treatment option, according to a large-scale study from Sweden. The daughter of how (or whether) to treat localized prostate cancer is controversial because, especially for older men, the tumor may not betterment far enough to cause real trouble during their remaining expected lifespan. In those cases, deferring therapy until there are signs of disease progression may be the better option.

The researchers looked at almost 6900 patients from the National Prostate Cancer Registry Sweden, seniority 70 or younger, who had localized prostate cancer and a unrefined or intermediate risk that the cancer would progress. From 1997 through December 2002, over 2000 patients were assigned to effective surveillance, close to 3400 underwent pink prostatectomy (removal of the prostate and some surrounding tissue), and more than 1400 received radiation therapy.

Complex Diagnostic Of Prostate Cancer

Complex Diagnostic Of Prostate Cancer.
Prostate biopsies that unify MRI technology with ultrasound appear to give men better facts regarding the seriousness of their cancer, a new study suggests. The unexplored technology - which uses MRI scans to help doctors biopsy very limited portions of the prostate - diagnosed 30 percent more high-risk cancers than guide prostate biopsies in men suspected of prostate cancer, researchers reported. These MRI-targeted biopsies also were better at weeding out low-risk prostate cancers that would not direction to a man's death, diagnosing 17 percent fewer low-grade tumors than sample biopsy, said senior author Dr Peter Pinto.

He is genius of the prostate cancer section at the US National Cancer Institute's Center for Cancer Research in Bethesda, MD. These results show that MRI-targeted biopsy is "a better avenue of biopsy that finds the aggressive tumors that need to be treated but also not finding those unoriginal microscopic low-grade tumors that are not clinically important but lead to overtreatment". Findings from the study are published in the Jan 27, 2015 Journal of the American Medical Association.

Doctors performing a required biopsy use ultrasound to tutor needles into a man's prostate gland, generally taking 12 core samples from prearranged sections. The problem is, this type of biopsy can be inaccurate, said haunt lead author Dr Mohummad Minhaj Siddiqui, an assistant professor of surgery at the University of Maryland School of Medicine and helmsman of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore.

And "Occasionally you may feel nostalgia for the cancer or you may glance the cancer, just get an bound of it, and then you don't know the full extent of the problem". In a targeted biopsy, MRIs of the suspected cancer are fused with real-time ultrasound images, creating a map of the prostate that enables doctors to pinpoint and analysis suspecting areas. Prostate cancer testing has become relatively controversial in recent years, with medical experts debating whether too many men are being diagnosed and treated for tumors that would not have led to their deaths.

Removal of the prostate gland can cause vile side effects, including impotence and incontinence, according to the US National Cancer Institute. But, even if a tumor isn't life-threatening, it can be psychologically recondite not to manage the tumor. To test the effectiveness of MRI-targeted biopsy, researchers examined just over 1000 men who were suspected of prostate cancer because of an jargon exceptional blood screening or rectal exam.

A New Prostate Cancers Treatment Strategy

A New Prostate Cancers Treatment Strategy.
Conventional long-headedness has it that turned on levels of testosterone help prostate cancers grow. However, a new, small retreat suggests that a treatment strategy called bipolar androgen therapy - where patients stand-in between low and high levels of testosterone - might make prostate tumors more responsive to measure hormonal therapy. As the researchers explained, the primary treatment for advanced prostate cancer is hormonal therapy, which lowers levels of testosterone to retard the tumor from growing. But there's a problem: Prostate cancer cells inevitably beaten the therapy by increasing their ability to suck up any leftover testosterone in the body.

The new strategy forces the tumor to respond again to higher testosterone levels, serving to reverse its resistance to standard therapy, the researchers say. If confirmed in several developing larger trials, "this could lead to a new treatment approach" for prostate cancers that have grown unaffected to hormonal therapy, said lead researcher Dr Michael Schweizer, an subordinate professor of oncology at the University of Washington School of Medicine in Seattle.

So "It needs to be stressed that bipolar androgen remedy is not ready for adoption into routine clinical practice, since these studies have not been completed. The backfire was published Jan 7, 2015 in the journal Science Translational Medicine. For the study, 16 men with hormone therapy-resistant prostate cancer received bipolar androgen therapy. Of these patients, seven had their cancer go into remission. In four men, tumors shrank, and in one man, tumors disappeared completely, the researchers report.

Smoking And Excess Weight Can Lead To A Cancer

Smoking And Excess Weight Can Lead To A Cancer.
Men with prostate cancer may upward their survival chances if they repay animal fats and carbohydrates in their parliament with healthy fats such as olive oils, nuts and avocados, new research suggests June 2013. Men who substituted 10 percent of their common calories from animal fats and carbs with such strong fats as olive oil, canola oil, nuts, seeds and avocados were 29 percent less acceptable to die from spreading prostate cancer and 26 percent less able to die from any other disease when compared to men who did not make this healthy swap, the study found. And a scarcely bit seems to go a long way.

Specifically, adding just one daily tablespoon of an oil-based salad dressing resulted in a 29 percent drop risk of dying from prostate cancer and a 13 percent reduce risk of dying from any other cause, the study contended. In the study, nearly 4600 men who had localized or non-spreading prostate cancer were followed for more than eight years, on average. During the study, 1064 men died.

Of these, 31 percent died from magnanimity disease, marginally more than 21 percent died as a issue of prostate cancer and slightly less than 21 percent died as a outcome of another type of cancer. The findings appeared online June 10 in JAMA Internal Medicine. The swot can't say for sure that including healthy fats in the food was responsible for the survival edge seen among men.

In Men With Prostate Cancer Observed Decrease In Penis Size

In Men With Prostate Cancer Observed Decrease In Penis Size.
A puny loads of men with prostate cancer complain that their penis appears to be shorter following treatment, doctors report. According to researchers from the Dana-Farber Cancer Institute and Brigham and Women's Cancer Center, Boston, these patients said that this unexpected surface make interfered with their dear relationships and made them regret the type of treatment they had chosen. "Prostate cancer is one of the few cancers where patients have a hand-picked of therapies, and because of the range of possible side effects, it can be a tough choice," ponder leader Dr Paul Nguyen, a radiation oncologist, said in a Dana-Farber news release.

So "This go into says that when penile shortening does occur, it really does affect patients and their mark of life. It's something we should be discussing up front so that it will help reduce treatment regrets". The affectation effect was most common among men who had prostatectomies, which is the surgical removal of the prostate, and those who had hormone-based psychotherapy coupled with radiation. Nguyen added that most patients are able to cope with just about any side effect if they identify about it in advance.

The study involved 948 men with recurrent prostate cancer. The men were enrolled in a registry that collects communication on patients whose prostate cancer shows signs of coming back after their earliest treatment. Most of the men were between the ages of 60 and 80. Of the men elaborate in the study, 54 percent had their prostate surgically removed, 24 percent received emanation combined with hormone-blocking treatment and 22 percent chose to undergo only radiation.

An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects

An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved health-giving prostate cancer vaccine, Provenge, is tried and true and has few sect effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both aegis and clinical data," said steer researcher Dr Simon J Hall, armchair of urology at Mount Sinai Medical Center in New York City.

This safeness data shows that there are very limited side effects, Hall added. The usefulness of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer ancillary effects than chemotherapy, which is the only other treatment option for these patients, Hall explained. In addition, Provenge has improved survival over chemotherapy, he added.

The common survival time for men given Provenge is 4,5 months, although some patients adage their lives extended by two to three years. "This is a newly handy treatment, with very limited side effects, compared to anything else that a man would be making allowance for in this state," Hall said. Hall was to present the results on Monday at the American Urological Association annual converging in San Francisco.

Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved prominence of sentience and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do play activities without any restrictions, the researchers noted.

Mass Screening For Prostate Cancer Can Have Unpleasant Consequences

Mass Screening For Prostate Cancer Can Have Unpleasant Consequences.
Health campaigns that highlight the hornet's nest of lachrymose screening rates for prostate cancer to nurture such screenings seem to have an unintended effect: They dissuade men from undergoing a prostate exam, a unexplored German study suggests search. The finding, reported in the stylish issue of Psychological Science, stems from knead by a research team from the University of Heidelberg that gauged the design to get screened for prostate cancer among men over the adulthood of 45 who reside in two German cities.

In earlier research, the learn authors had found that men who had never had such screenings tended to accept that most men hadn't either. In the current effort, the set exposed men who had never been screened to one of two health report statements: either that only 18 percent of German men had been screened in the old days year, or that 65 percent of men had been screened.

PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer

PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer.
A skill that urologists had hoped would make out it imaginable to tell the difference men with prostate cancer who need treatment from those who would only for watchful waiting didn't work well, researchers report. The technique, called PSA kinetics, measures changes in the place at which the prostate gland produces a protein called prostate-specific antigen buy am 2201 1 gram. A significant enlargement in PSA kinetics, exact by the term during which PSA production doubles or increases at a speedy rate, is supposed to indicate the need for treatment, by radiation remedy or surgery.

PSA kinetics has long been used to measure the effectiveness of treatment. A handful of cancer centers have started to use it as a practical method of distinguishing aggressive cancers that require treatment from those that are so slow-growing that they can safely be hand alone.

Recent studies indicating that many men with slow-growing prostate cancers weather unnecessary treatment have given exigency to the search for such a tool, especially considering that side effects of treatment can allow for incontinence and impotence. But the study indicates that "PSA kinetics doesn't seem to be enough to show you who you should follow and who you should treat," said Dr Ashley E Ross, a urology abiding at the Johns Hopkins University Brady Urological Institute, and model initiator of a report on the technique published online May 3 in the Journal of Clinical Oncology.

The check in describes the results of PSA kinetics measurements of 290 men with low-grade prostate cancer - the good that often doesn't coerce curing - for an average of 2,9 years. The results of PSA tests were compared with biopsies - pile samples - that well-thought-out the progression of the cancers.

The suffering is part of a study, under supervision of Dr H Ballentine Carter, top dog of the division of adult urology at the Brady Urological Institute, that began in 1994. Men in the endeavour had PSA tests every six months and biopsies every year.